Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Bright Minds Biosciences's shares outstanding for the quarter that ended in Mar. 2026 was 9.81 Mil.
Bright Minds Biosciences's quarterly shares outstanding
increased
from Dec. 2025 (7.79 Mil) to Mar. 2026 (9.81 Mil).
It means Bright Minds Biosciencesissued new shares from Dec. 2025 to Mar. 2026 .
Bright Minds Biosciences's annual shares outstanding
increased
from Sep. 2024 (4.52 Mil) to Sep. 2025 (7.64 Mil).
It means Bright Minds Biosciencesissued new shares from Sep. 2024 to Sep. 2025 .
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
Bright Minds Biosciences Shares Outstanding (EOP) Related Terms
Bright Minds Biosciences Shares Outstanding (EOP) Historical Data
* Premium members only.
The historical data trend for Bright Minds Biosciences's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DRUG vs VRTX, REGN, ALNY: Shares Outstanding (EOP) Comparison
For the Biotechnology subindustry, Bright Minds Biosciences's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bright Minds Biosciences Shares Outstanding (EOP) vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bright Minds Biosciences's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where Bright Minds Biosciences's Shares Outstanding (EOP) falls into.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
What does a Shares Outstanding (EOP) of 9.81 Mil mean?
Bright Minds Biosciences (DRUG) has a Shares Outstanding (EOP) of 9.81 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Bright Minds Biosciences and its competitors.
Is Bright Minds Biosciences' Shares Outstanding (EOP) too high?
Bright Minds Biosciences' current Shares Outstanding (EOP) is 9.81 Mil. Overall, Bright Minds Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Bright Minds Biosciences' Shares Outstanding (EOP) compare to VRTX and REGN?
Bright Minds Biosciences' Shares Outstanding (EOP) of 9.81 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Bright Minds Biosciences and its competitors. Bright Minds Biosciences's current Shares Outstanding (EOP) is 9.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bright Minds Biosciences stock overvalued right now?
Bright Minds Biosciences (DRUG) has a current Shares Outstanding (EOP) of 9.81 Mil. The current Shares Outstanding (EOP) is 9.81 Mil. Bright Minds Biosciences' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Bright Minds Biosciences (DRUG), the current Shares Outstanding (EOP) is 9.81 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
34GF Score
Get the complete analysis for DRUG
Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DRUG has been successfully added to your 
